Cerulean reviews clinical assets, nanoparticle-drug conjugates

Cerulean Pharma Inc. (NSDQ:CERU) said today that its board of directors launched a strategic review of its assests, considering alternatives for its clinical assets and nanoparticle-drug conjugate platform.

Waltham, Mass.-based Cerulean said it could consider a sale, a merger, or an investment into the company. The board is also floating the possibility of a sale or license of the company’s assets. The company cautioned that its review may not result in any transaction.

Get the full story at our sister site, Drug Delivery Business News.

The post Cerulean reviews clinical assets, nanoparticle-drug conjugates appeared first on MassDevice.

from MassDevice http://ift.tt/2kTfWnd